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N ormal adult human keratinocytes in monolayer culture and 
SCL-1 , a skin-derived squamous-cell carcinoma cell line, 
were investigated for the expression of receptors for insulin-
like growth factors (IGF) and insulin. As demonstrated by 
affinity crosslinking, radiolabeled IGF-1, IGF-2, and insulin 
bound specifically to both cel l types. Each cell expressed type 
I IGF receptors, with affinity for IGF-1 > IGF-2 ~ insulin. 
Insulin receptors, with highest affinity for insulin, were also 
present on both cells. However, keratinocytes and SCL-1 
cells differed in 1251-IGF-2 binding. 1251-IGF-2-bound to 
both type I and type II IGF receptors in normal keratinocytes, 
but bound predominantly to membrane-associated IGF bind-
ing proteins in SCL-1. 
IGF-1 was slightly more potent than IGF-2 in stimulating 
growth of both keratinocytes and SCL-1 cells. In keratino-
cytes, concentrations of IGF-1 ranging from 5-100 ng/ml, 
and of IGF-2 from 50 - 100 ngjml, resulted in a significant 
increase in cell number. At the maximum dose of 100 ng/ ml , 
I nsulin and the insulin-like growth fac tors {IGF) constitute a farui ly of related peptides with mitogenic action in a variety of cel ls [1 ,2]. IGF-1 and IGF-2, w hich are proteins of 70 and 67 amino acids, respectively, are homologous to proinsulin in both sequence and structure. In most tissues and cell lines, 
distinct high affinity receptors for insulin, IGF-1 , and IGF-2 are 
present. The insulin receptor, which has a lower affinity for the 
IGFs, and the type I IGF receptor, w hich has a high affinity for 
IGF-1 and weaker affini ty for IGF-2 and insulin, are homologous 
heterotetrameric structures . Each is composed of two alpha and two 
beta subunits that migrate on electrophoresis under reducing condi-
tions to approximately 130 kD and 95 kD, respectively [3,4]. In 
contrast, the type IIIGF receptor, with a high affini ty for IGF-2 and 
very low affinity for the other ligands, is a monomer that migrates 
to approximately 250 kD. It is identical to the mannose-6-phos-
phate receptor [5] and is involved in the transport of lysosomal 
enzymes between the endoplasmic reticu lum, lysosomal compart-
ments, and cell membrane. Its role in med iating IGF action is unde-
fined. 
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either IGF-1 or IGF-2 caused a 2.3-times increase in cell 
number. In SCL-1 cells, IGF-1 was more potent than IGF-2 
or insulin at lower concentrations, but either IGF-1 or IGF-2 
at the maximal concentration of 333 ng/ml stimulated a 
4.7-times increase in thymidine incorporation. The stimula-
tory effect of insulin in SCL-1 was 10- 50 times less potent 
than that of the IGF. The effect of either IGF on SCL-1 was 
completely inhibited by the type I IGF receptor antibody 
alphaiR-3, suggesting that both IGFs are mitogenic through 
the type I IGF receptor. Insulin action was partially blocked 
by alphaiR-3 , suggesting that insulin can act through both 
the insuli~ and type I IGF receptors . It thus appears that 
IGF-1 and IGF-2 are mitogens for normal and transformed 
human keratinocytes and that their actions are primarily me-
diated through the type I IGF receptor, whereas insulin is a 
mitogen through both the IGF-1 receptor and the insulin 
receptor. J ln11est D ermatol 96:104-110, 1991 
The IGF, but not insulin, also bind with high affinity to several 
smaller binding proteins {IGFBPs) [6 ,7] . Three distinct human 
IGF-binding proteins (hBP), with protein cores of approximately 
25, 31, and 29 kD, have been sequenced [8 -11] and have recently 
been termed IGFBP-1, -2, and -3 , respectively. In its glycosylated 
form, hBP-3 1s a component of th e 150-kD IGF binding protein 
complex found 111 human serum [12] . Additional IGFBP have been 
identified. but not completely.sequenced [13, 14]. IGFBP have been 
charactenzed 111 a van ety ofb10logic fluids, such as serum, amniotic 
fluid ~ and cerebrospinal fluid , and in the conditioned media of many 
celllmes (15 -2 1]. Although these binding proteins modulate access 
of IGF to their receptors [22- 24], the physiologic role of IGFBP 
remains unclear (25- 28]. 
Hum~n keratinocytes respond in vitro to a variety of growth 
factors, mcludm~ ep1dermal growth factor, basic fibroblas t growth 
factor, transformmg growth factors a and /3, insulin, and the insu-
l~n-like growth factors [29-32]. Normal keratinocytes can be rou-
tmely cultured 111 a serum-free medium supplemented with EGF, 
transferrin, hydrocortisone, and either insulin or IGF-1 [33] . W e 
and others have previously identified spcrcific binding of insulin, 
IGF-1, and IGF-2 to human keratinocytes (34 ,35] and have demon-
strated that both IGF-1 and insulin stimulate DNA synthesis and 
cell proliferation in human keratinocytes [29,36], as well as in der-
mal fibrobl~sts [37] . These findin gs are of potential importance in 
the evaluation of these growth factors in wound healing [38- 40] 
and in hyperproliferative skin disorders . To further characterize the 
role of IGF-1, IGF-2, and insulin in human skin, we have investi-
gated IGF and insulin receptors and biologic actions both in human 
keratinocytes and in a skin-derived squamous-cell carcinoma cell 
line, SCL-1. 
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MATERIALS AND METHODS 
Cells The human squamous-cell carcinoma line SCL-1, origi-
nall y obtained from a poorly differentiated squamous-cell carci-
noma of the skin, was provided by Dr. N . Fusenig (Heidelberg, 
West Germany). Cell s were maintained in monolayer culture in 25 
cm2 plastic culture flas ks (Corning, Corning, NY) in 6% C02 at 
37 °C, utilizing Dulbecco's modified Eagle's medium (DMEM) (Ir-
vine Scientific, Santa Ana, CA) with 10% fetal bovine serum (FBS; 
Gibco, Gra nd Island, NY) and 2 mM glutamine. Medium was re-
p laced every 3- 4 d and cells were spli t 1:10 weekly, using 0.3% 
trypsin/0.1% EDT A. . . . 
Suspensions of human keratmocytes were obtamed from elective 
smgery in adults by soakmg 0.1 -mm stnps of kerat~med s_km f~r 
45 min at 37"C 111 0. 3% trypsm/0. 1% EDTA, separatmg ep1denms 
from dermis, and scraping basal epidermal cells into keratinocyte 
growth medium (KGM) (Clonetics, San Diego, CA). KGM consists 
of MCDB 153 medium suppl emented with 5 ng/ml EGF, 5 ,ugjml 
insulin, 0.4 Jtgjml hydrocortisone, 0.1 mM ethanolamine, 0 .1 mM 
phosphoethanolamine, 150 ,ug/ml bovine pituitary extract (BPE), 
and amino acids [32]. 
Materials Recombinant DNA-dei·ived Thr59-IGF-1 was pur-
chased from Amgen Biologicals (Thousand Oaks, CA). Synthetic 
IGF-2 for iodination was provided by Dr. C. H. Li (San Francisco, 
CA). IGF-1, IGF-2, and insulin were iodinated by a modification of 
the chloramine T method (42] to a specifi c activi ty of 150-300 
,uCi/ ,ug. Recombinant IGF-2, utilized for inhibition of crosslinking 
and for thymidine incorporation studies, and recombinant human 
crystalline insul in were provided by Dr. M. Smith of Eli Li lly (India-
napolis, IN) . AlphaiR-3, a monoclonal antibody to the human type 
I IGF receptor, was kindly provided by Dr. S. J acobs (Wellcome, 
Research Triangle, NC) . 
Membrane Preparation SCL-1 cell s or kerat inocytes were 
grown to confluence in 10-Cin dishes, switched to SFM for 48 h , 
washed 5 times with PBS, and then detached with cold PBS and 
1 mM EDTA. Ce lls were pelleted, resuspended in an homogeniza-
tion buffer of 10 mM N aP04 , 1 mM EDTA, 0.25 M sucrose, 
0.15 M N aCI, 2 mM iodoacetic acid , and 1 mM phenylmeth yl sul-
fony l fluorid e (fresh ly added from stock in 100 mM absolute eth-
anol) (PMSF, Sigma, St. Louis, MO) at pH 7.4, and then sonicated 
for 90 sec. The lysate was centrifuged at 4000 X g for 30 min at 
4 oc, and the result ing supernatant was centrifu ged at 40,000 X g 
for 1 h at 4 °C. The pellet was resuspended in a solubilization buffer 
(50 mM HEPES, 0.15 M N aCl, 2 mM MgS04 , 1 mM PMSF at pH 
7 .4), recentrifuged at 40,000 X g, resuspended, and assayed for pro-
tein content using the BCA protein assay [43]. 
Affinity Crosslinking Cross linking of intact monolayers or 
crude membrane prepa rat ions utilized various modifications of the 
crosslinking technique described by Adams et al [ 44]. To crosslink 
crude membranes, 125 Jtg membrane protein was incubated with 
300,000 cpm of rad ioligand with or without unl abeled peptide in 
500 ,ul of 50 mM Tris, 0.5% BSA, at pH 7.4 overnight at 4 oc in 
1.5-ml microfu ge tubes. Membranes were then pell eted at 
10,000 X g and washed once in Tris buffer. The pellet was resus-
pended in 1 ml of 50 mM Tris buffer and 1 mM disuccinimidyl 
suberate (DSS, Pierce, Rockford, IL) . After 15 min at 4°C, the 
crosslinking reaction was quenched by the addition of 200 ,ul of 
50 mM Tris H Cl and 5 mM EDTA. Membranes were pelleted 
again and solubilized in 150 ,ul of sodium dodecyl sulfate (SDS) 
sample buffer (62.5 mM Tris, 10% glycerol, 2.35% SDS) with or 
without 100 mM dithiothreitol (DTT). 
To cross link intact cell s, cells were grow n to con.fluence in 21-
mm wells and transferred to SFM for 48 h. Monolayers were 
washed repeated ly in HEPES buffer, incubated with 300,000 cpm 
of radioli gand in 0.75 ml ofHEPES buffer with 0.5% BSA, pH 7.4 
overnight at 4 o C, washed, and crosslinked as above, then solubi-
lized in SDS sa mple buffer with 5% 2-mercaptoethanol (2-ME). 
Membrane and intact cell samples were heated to 95 o C for 5 min 
prior to electrophoresis on an SDS-polyacryl amide ge l at 60 volts, 
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utilizing high molecular weight standards from BioRad (Rich-
mond, CA). Gels were dried for 2 h at sooc and exposed to XAR 
film (Kodak, Rochester, NY) at -70°C. To quantify binding to 
intact cells, bands on autoradiograms of gels representing three sepa-
rate crosslinking experiments were read· in an LKB Ultrascan LX 
densitometer. 
Cell Proliferation Twenty to fifty thousand passaged keratino-
cytes were plated in 3.5-cm wells and maintained in KGM or KDM 
for 24 h. All cell s were then washed twice with' sterile PBS and fed 
with KDM without added insulin, but with variable concentrations 
of study peptides, in duplicate or triplicate wells at a volume of2 ml 
per well. Media were aspira ted and replaced with fres h study media 
at 4 d. At 7 d, cells were removed with 0.3% trypsin/0.1% EDTA 
and counted in triplicate in a Coulter counter. 
Thymidine Incorporation SCL-1 cells were grown to con-
fluence in 16-mm 24-well plates (Costar, Cambridge, MA) and 
placed in SFM for 24 h. In experiments utilizing the anti - type-I 
receptor antibody alphaiR-3 , cells were pretreated with 7.5 ,ugjml 
of antibody for 1 h. Cells were then incubated with varying con-
centrations of peptides in 0.5 ml DMEM with 0.02% BSA at 37"C. 
In pilot stud ies, thymidine was added from 16-28 h after the onset 
of incubation. In subsequent studies, 0.1 ,uC i JH-thymidine (New 
England Nuclear, Boston, MA) were added to each well at 20 h. At 
24 h cell monolayers were washed twice w ith cold PBS, precipi-
tated with 1 ml of 10% trichloracetic acid (TCA) for 10 min at 
- 20°C, and washed again with cold TCA. Precipitates were solu-
bilized with 0.5 ml of 0.25 N NaOH for 1 h, and radioactivi ty 
counted in a liquid scintillation counter (Beckman). 
Statistical Analysis Data from keratinocyte proliferation and 
SCL-1 thymidine incorporation were eva luated using a Student t 
test. 
RESULTS 
Affinity Cross linking of Keratinocyte Membranes Figure 1 
shows an autoradiogram of crude keratinocyte membrane sampl es 
crosslinked to 1251-IGF-1 and 1251-IGF-2 in the absence or presence 
of200 ngjml of unlabeled peptides, and run on a grad ient gel under 
reducing conditions. Binding of 1251-insulin was fain tly present and 
is not shown. 125!-IGF-1 predominantly labeled the type I receptor, 
seen as the 130-kD alpha subunit "nd a presumed alpha-alpha dimer 
at approximately 260 kD. Binding to each of these moieties was 
displaced by IGF-1 > IGF-2 > insulin (lanes 2-4) . 1251-IGF-2 
(laN es 5-8) faintly labels a type I receptor alpha subunit. However, 
it principally labels a moiety (arrow at Mr = 250,000) that appears 
sma ller than the alpha-alpha dimer from la11 es 1-4 and is displaced 
with a pattern different than that of the alpha-alpha dimer. This 
approximate 250-kD band was displaced by IGF-2 (lane 7), only 
weakly by IGF-1 (lane 6), and not at all by insulin (/ail e 8). We 
conclude that this band represents a type-II IGF receptor, which has 
high affinity for IGF-2. Of note, there was littl e apparent specific 
binding of either 1251-IGF-1 (B0 , I aile 1) or 125!-IGF-2 (B0 , !aile 5) to 
any membrane-associated IGFBP in keratinocyte membranes. 
Proliferation of Keratinocytes Figure 2 combines the results 
from six replicate experiments investigating the effect of 5-1 00 
ngjml (0.65 -13 nM) of IGF-1 or IGF-2 on proliferation of pas-
saged human keratinocytes in vitro. Only IGF-1 caused a significant 
increase in cell number at lower concentrations (5 - 20 ngjml) . 
IGF-2 stimulated a signifiqmt increase at doses of 50 and 100 ng/ 
mi. At 100 ngjml (1 3 nM), IGF-1 and IGF-2 resulted in virtually 
identica l 135% increases in cell number under these experimental 
conditions. The responses to 100 ng/ml of IGF-1 or IGF-2 were 
significant at p < 0.01. 
Crosslinking ofSCL-1 Membranes We crosslinked 1251-IGF-
1, 125!-IGF-2, and 125!-insulin to SCL-1membrane preparations and 
monolayers. Fig 3 presents an autorad iogram of crude membrane 
samples crosslinked to each of the radioligands in the absence or 
presence of unlabeled peptides, and run on a gradi ent gel under 
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Figure 1. Affinity labeling of keratinocyte membranes. Shown is an au~o­
radiograph of 5-15% SDS-polyacrylamide _gel electrophoresis of a keratm-
ocyte membrane preparation {100 Jlg protem per latle) mcubated for 2 h at 
23 ' C with 1251-IGF-1 (lan es 1-4) or 1251-IGF-2 (lan es 5-8), crosslinked and 
reduced. Lanes 1 and 5, no unlabeled peptide present; lanes 2 and 6, 200 
ngjml unlabeled IGF-1; lanes 3 and 7, 200 ngjml IGF-2; latus 4 and 8, 200 
ng/ml insulin. Arro!Vs point to presumed type II receptor (Mr 250,000) and 
type I receptor alpha subunit (Mr 130,000). 
reducing conditions. 1251-IGF-1 (lanes 1-4) speci~cally labeled 
proteins at 130 and 260 kD, presumably representu~g the alpha 
subunit of the type-I IGF receptor and an alpha-alpha d1mer, respec-
tively. Both bands were inhibited by unlabeled_IGF-1 (lane 2) . Only 
the higher concentration of unlabeled msuh~ (5 ,ug/ml, lane 4) 
partially inhibited IGF-1 binding, consistent :Vtth a type-I receptor, 
which has low affinity for insulin. 1GF-1 m SCL-1 also bound 
specifically to a pair of smaller proteins, presumabl~ membrane-as-
sociated IGF binding proteins (IGFBP), at approx1~ately ~3 and 
45 kD. Insulin, even at the higher concentration, dtd not d1splace 
IGF-1 from these proteins. These IGFBP were not present on the 
keratinocyte membranes shown in Fig 1. 
Crosslinking of 125J-IGF-2 to SCL-1 membranes (lanes 5-8), on 
the other hand, did not clearly label a type-I or type-II IGF rec~pt~r, 
although a very faint band at approximately 250-260 k~ IS dis-
placed in a pattern consistent with either an alpha-alpha drmer of 
the type-! IGF receptor or a type-11 receptor. Other gels (not 
shown) did demonstrate faint alpha subunits consistent with 1251-
IGF-2 labeling of a type-1 IGF receptor, but no type-II receptor 
could ever be demonstrated. IGF-2 did bind to the membrane-asso-
ciated BP at 43 and 45 kD, with specific inhibition by IGF-2 (lane 
6) or IGF-1 (lan e 7), but not insulin (lane B). In the presence of 
unlabeled IGF-1 or IGF-2, 1251-IGF-2 also labeled a pair of bands at 
50 - 60 kD. These bands, which do not correlate with any known 
IGFBP, were consistently present in SCL-1 membranes crosslinked 
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Figure 2. Proliferation of keratinocytes. Keratinocytes in 3.5-cm wells 
were maintained in insulin-free KDM with variable concentrations of study 
peptides, in multiple wells. Media were aspirated and replaced with fresh 
study media at 4 d, and harvested and counted at 7 d. Means ± SEM, com-
bined data of six separate experiments; asterisk, difference from control value 
significant at p < 0.05. 
with 1251-IGF-2, but they were not seen with 1251-IGF-1 and were 
not displaced by even higher concentrations of unlabeled IGF. Fur-
thermore, these 50-60 kD bands were not seen when 1251-IGF-2 
was crosslinked to intact SCL-1 cells. 
SCL-1 membranes crosslinked ~ith 1251-insulin (lanes 9-11) 
demonstrate faint bands at 130 and 260 kD, representing the alpha 
subunit and alpha-alpha dimer of the insulin receptor, because 150 
ng/ml of insulin (lane 11), but not 1GF-1 (lane 1 0), displaced 1251-
insulin from the receptor. As expected, there was no insulin binding 
to the membrane-associated IGFBP. 
Thus, affinity crosslinking to a crude SCL-1 membrane prepara-
tion demonstrated: 1) a type-1 IGF receptor with high affinity for 
IGF-1 and low affinity for insulin; 2) a pair of membrane-associated 
IGFBP, with high affinity for IGF-1 and IGF-2, but not insulin; and 
3) an insulin receptor. In contrast to keratinocytes, a type II receptor 
was not visualized in SCL-1 membranes. 
Crosslinking ofSCL-1 Monolayers These results were further 
evaluated by crosslinking to intact cell monolayers (densitometric 
data presented in Fig 4) . Crosslinking of 1251-IGF-1 under reducing 
conditions demonstrated that the 130-kD alpha subunit of the type-
1 IGF receptor was displaced by IGF-1 > IGF-2 ~ insulin. The 
receptor antibody alphaiR-3 (10 ,ug/ml) almost completely inhib-
ited binding of 1251-IGF-1 to its high affinity receptor. 1251-insulin 
also crosslinked to a 130-kD binding subunit on the SCL-1 mono-
layer and was displaced by insulin ~ IGF-1 = IGF-2. In the pres-
ence of alphaiR-3, insulin binding to the 130-kD alpha subunit was 
diminished by 25%. Because alphaiR-3 is specific for the type-I 1GF 
receptor, this finding suggests that the 130-kD band labeled by 
125!-insulin may represent a combination of insulin binding to the 
more abundant type-! IGF receptor and to the high-affinity insulin 
receptor. 
IGF and Insulin Stimulation ofDNA Synthesis in SCL-1 In 
order to evaluate the biologic action of the IGF and insulin in 
SCL-1, we utilized thymidine incorporation as a measure of cellular 
DNA synthesis, previously shown to correlate well with insulin-
stimulated cell proliferation in keratinocytes [29]. SCL-1 cells incor-
porated increased amounts of thymidine in the presence ofiGF-1, 
IGF-2, and insulin (Fig 5). At concentrations greater than 10 ng/ml 
(0.65 nM), IGF-1 and IGF-2 consistently and significantly (p > 
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Figure 3. Affinity labeling of SCL-1 mem-
branes. 125 J.Lg of SCL-1 membrane protein was 
crosslinked to 1251-IGF-1 (lanes 1-4), 125!-IGF-2 
(lan es 5-8), or 12SJ-insnlin (lan es 9-11), and run 
under reducing conditions on a 3-12% gradient 
50S-polyacrylamide gel. Crosslinking was per-
formed in the absence of un labeled peptide (larr es 
1, 5, 9) and in the presence of 150 ng/ml IGF-1 
(lan es 2, 7, 10), 150 ng/ml IGF-2 (lane 6), 150 
ng/ ml insulin (lan es 3, 8, 11), or 5 J.Lg/ml insulin 
(lane 4). The gel was exposed for 1 week for 
t2SJ-IGF-1 and 1251-IGF-2 lanes, and for 4 weeks 
for 1251-insu]in. Thick arrow, receptor alpha sub-
units; tlri11 arrow, IGFBP. 
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0.001) stimulated thymidine incorporation. At concentrations of 10 
ng/ml and 100 ng/ml (13 nM), IGF-1 was more potent than IGF-2, 
but the IGF were equipotent at the highest concentration tested, 
333 ng/ml (44 nM). Insulin was roughly 10-50 times less potent 
than IGF-1 in stimulating incorporation, but significantly increased 
incorporation at higher concentrations. 
The specific anti- type I receptor antibody alphaiR-3 was capable 
of reproducibly blocking the increase in thymidine incorporation 
with all three peptides (Fig 6). Equivalent doses ofiGF-1 and IGF-2 
(100 ng/ml, or 13 nM), and a 20 times higher dose of insulin, 
resulted in approximately equivalent levels of thymidine incorpora-
tion. AlphaiR-3 inhibited virtually all of the increased thymidine 
incorporation induced by IGF-1 or IGF-2 and inhibited 35% of the 
increase caused by insulin. We interpret this partial inhibition of 
insulin's action as evidence that insulin has a mitogenic action 
through both its own receptor and the type I receptor, whereas 
IGF-1 and IGF-2 appear to be acting only through the type I IGF 
receptor. 
DISCUSSION 
We have demonstrated the expression of type I (IGF-1) receptors in 
two cells of epidermal derivation, passaged keratinocytes and the 
squamous-cell carcinoma cell line, SCL-1. From affinity crosslink-
ing studies of both cells, these appear to be classical type I IGF 
receptors, with an affinity for IGF-2 only slightly lower than for 
IGF-1 itself, and a much lower affinity for insulin. These results are 
consistent with the affinities demonstrated in Chinese hamster 
ovary cells transfected with human IGF-1 receptor eDNA [45]. 
Insulin receptors, which have a higher affinity for insulin than the 
IGF, were also present but less prominent than the type I IGF 
receptors on both cells. 
Although IGF-2 bound readily to both keratinocyte and SCL-1 
membranes and cells, it bound to different proteins in the two cell 
types. In keratinocyte membrane preparations, virtually all specific 
IGF-2 binding was to the type I and type II (IGF-2/M6P) receptors . 
In SCL-1 cells, in contrast, type I and type II IGF receptors were not 
prominent. Although unlabeled IGF-2 was capable of potently dis-
placing 125I-IGF-1 from the type I receptor, which confirms that 
IGF-2 binds to the type I IGF receptor, bands representing ' 251-IGF-
2 labeling of the type I IGF receptor could be seen only faintly, or 
not at all, in a series of gels utilizing SCL-1 membranes or cells. The 
presence of type II receptors, although not excluded, could not be 
demonstrated. Instead, virtually all of the IGF-2 binding to SCL-1 
membranes and cel ls (and a substantial proportion of IGF-1 bind-
ing) was to IGF binding proteins. Our results suggest that IGF-2 has 
a markedly greater affinity for IGFBP than for the type I or type II 
IGF receptor. The presence of high-affinity membrane-associated 
IGFBP in SCL-1, as opposed to their virtual absence in keratino-
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Figure 4. Affinity crosslinking of SCL-1 monolayers. Data are presented in 
densitometric analysis of 130-kD bands in autoradiographs of 5- 15% gra-
dient SDS-PAGE of intact SCL-1 cells crosslinked to 1251-IGF-1 and 12SJ.in-
sulin and electrophoresed under reducing conditions. Cells were incubated 
overnight at 4 ·c with 400,000 cpm 1251-IGF-1 or 125J.insulin in the absence 
or presence of 200 ng/ml of IGF-1, IGF-2, and insulin, or 10 ug/ml of 
alphaiR-3 , as indicated. Data represent the mean (± SEM) of B/Bo of lanes 
from three separate gels run under identical conditions, where B was deter-
mined as peak height by laser densitometer. 
cytes, may partly explain the difficulty in visualization of 125I-IGF-2 
binding to type I receptors on SCL-1 . 
Five IGF binding proteins have recently been identified. Al-
though they are generally thought to be inhibitory, their physio-
logic role is poorly defined. The significance of the presence or 
absence of membrane-associated IGFBP is not at all understood . 
The presence of membrane-associated IGFBP on SCL-1 cells, but 
not keratinocytes, does correlate with apparently greater amounts of 
IGFBP in the conditioned media ofSCL- 1 compared with keratino-
cytes (data not presented). Because the characterization of mem-
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Figure 5. 3H-thymidine incorporation by SCL-1 cells in the presence of 
varymg concentrations of peptide. Cells were grown to confluence in 16-
mm wells, switched to serum-free media for 24 h, washed, and incubated at 
37"C in 0.5 ml DMEM with 0.02% BSA, with or without indicated con-
centrations of peptide. At 20 h, ' H-thymidine was added, and at 24 h the 
cells were treated with TCA, and the resulting precipitates solubilized and 
counted. Mean of control wells (absence of peptide) equals 100%; points, 
mean ± SEM of a total of seven wells from two experiments; asterisk, mean is 
significantly different from the control value at p < 0.001 by t test. 
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Figure 6. Effect of alphaiR-3 on ' H-thymidine incorporation in SCL-1 
cells. Methods employed were as described in Fig 5, except 7.5 ,ug/ ml of 
alpha!R-3 wa~ added 1 h prior to addition of 100 ngjml IGF-1 or IGF-2, or 
2 ,ug/ mlmsuhn. D~ta rq~resent ~can ± SEM of six wells from two separate 
expenments under tdenttcal condttwns. Alpha!R-3 inhibition ofiGF-1 and 
IGF-2-stunulated 3H-thymidine incorporation was significant at p < 0.001 . 
brane-associated IGFBP has lagged behind the identification of 
IGFBP in cell-c~nditioned media and various body fluids, little is 
known about_their functio~ or their relationship to binding proteins 
m the condmoned media. Whether membrane association of 
IGFBP merely reflects adherence of conditioned-media BPs to 
membranes is not known. However, membrane-associated BP were 
als~ present in_ our crosslinked samples of intact cells, suggesting 
their presence is not merely an artifact of membrane preparation. 
. In adult human keratmocytes, we have demonstrated a prolifera-
tive respo~se to I_G F-1 and to IGF-2. IGF-1 was more potent, caus-
mg a sigmficant mcrease in cell number at 5 ng/ml (0.65 nM) and 
higher ,. whereas IGF-2 stimulated a significant response at a 10 
tlmes lugher concentratiOn, 50 ng/ml. However, the maximal re-
sponses were s~milar, suggesting that the action of both IGF-1 and 
IGF-2 m keratmocytes may be mediated by the IGF-1 receptor. In 
our studies, IGF-1 and JGF-2 were both more potent than insulin 
(data not show~), because we were not able to demonstrate any 
response to msulm at concentrations less than 100 ng/ mi. We specu-
late that msulm atthe h1gh doses utilized in m edia for keratinocyte 
culture m~y be pr_imanly effective via the type I IGF receptor. 
Two pn~r studies have utilized mouse keratinocyte lines to com-
pare b10logic responses to these peptides. In both, IGF-1 and IGF-2 
v.:ere 10-50 ti~es more potent than insulin in augmenting thyrni-
dme mco_rporauon [46,47] . Shipley and Pittelkow [33] had ob-
served, W1t1_10ut presenting-data, that as little as 10 ng/ml of IGF-1 
cou~d substitute for the 5 .Ug/ml of insulin, present in a commonly 
utihzed human keratinocyte medium. In our previous report, SO 
n!?/ml of IGF-1 was roughly equivalent to 10 .ug/ml of insulin in 
stn~ulatmg hum~n kera~inocyte proliferation [36]. In studies com-
~anng EGF and ms~lm 111 the stimulation of thymidine incorpora-
tiOn versus cell prohferat10n m human keratinocytes, 3-5 .ug/ ml of 
msulm w ere reqmred for maximal stimulation [29]. The data from 
these studies sugge~t not 01:ly that insulin is a less-potent growth 
factor than IGF-1 111 keratmocytes, but also that insulin may act 
primarily through the IGF-1 receptor. 
_As an alterna~ive . approa~h to the question of which receptor is 
biOlogically active m keratu-~ocytes, we chose to assay thymidine 
mcorporauon 111 another epidermal cell line, SCL-1, which ex-
pressed rou~hly equivalent p_roportions ofiGF-1 and insulin recep-
tors as keratmocytes by affimty crosslinking. The thymidine incor-
poration studies in SCL-1 cells clearly revealed that both IGF-1 and 
IGF-2 are potent stimulators of DNA synthesis. The actions ofboth 
peptides appear to be mediated primarily by the IGF-1 (type I) 
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receptor, as the mitogenic effects were completely inhibited by 
alphaiR-3. This result can be predicted from the high affinity of the 
IGF-1 receptor for IGF-2. Action of IGF-2 through the type I 
receptor has been demonstrated previously i~ other cell lines, in-
cluding dermal fibroblasts [48]. Thus, SCL-1ts another cell type 111 
which a biologic act ion of IGF-2 is mediated through the rype I 
receptor instead of the type II receptor [49]. Indeed, in SCL-1 we 
have not been able to even demonstrate the presence of a type II IG F 
receptor. 
The IGF were clearly more potent than insulin in stimulating 
thymidine incorporation in SCL-1 cell s. IGF-1 was the most potent 
growth factor at lower concentrations,IGF~1 and IGF-2 were equi-
potent at hig her concentrations, and msulm was least potent. Al-
though the relative pot.encies in both ce.ll type~ are con.sistent with 
mitogenic effects of this famdy of peptides bemg mediated by the 
rype I receptor, the effects of alph aiR-3 support the hypothesis that 
only part of the insulin action in SCL-1 cel ls is mediated by the type 
1 IGF receptor. We specu late that keratinocytes and SCL-1 cells are 
fundamenta lly simil ar in having a potent mitogenic response 
through the type I IGF receptor, stimulated by IGF-1 at low con-
centrations and insulin at hi g h concentrations. In SCL-1, the mito-
genic response stim ul ated by IGF-1 alone was more potent than that 
stimulated by msulm through the m sulm receptor and the IGF-1 
receptor combined. However, in SCL-1, and presumably in kerati-
nocytes as well , insulin is capable of a mitogenic action through the 
insulin receptor as well. 
In summary, we have demonstrated a biologic role for the insu-
lin-like growth factors in both normal human keratinocytes and a 
squamous-cell carcinoma cell line derived from human skin. Type I 
IGF receptors were present on both rypes of cells. In contrast, rype II 
receptors were present only on keratinocytes, and membrane-asso-
ciated IGF binding proteins were seen only on SCL-1 cells. IGF-1 
and IGF-2 were potent stimulators of cell proliferation in keratino-
cytes. The IGFs were 10-50 times more potent than insulin in 
stimulating thymidine incorporation in SCL-1, and all of the mito-
genic effect of IGF-2 and part of the effect of insulin were mediated 
by the type I IGF receptor. These data su ggest the IGFs are impor-
tant in epidermal cell growth and regeneration. 
We tha11k Ms. Eva Pjcttdt for her ge11erous techt~ica l assista11ce. 
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